Maxadilan, the vasodilator/immunomodulator from Lutzomyia longipalpis sand fly saliva, stimulates haematopoiesis in mice

Parasite Immunology

Volumn 24, Issue 8, 2002, Pages 437-446

  Guilpin, Valerie O ^a   Swardson Olver, Christine ^a   Nosbisch, Leanna ^a   Titus, Richard G ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Haematopoiesis; IL 6; Maxadilan; Pituitary adenylate cyclase activating polypeptide; Sand flies

Indexed keywords

ADENYLATE CYCLASE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MAXADILAN; RECEPTOR; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEMATOPOIESIS; INFECTION SENSITIVITY; LEISHMANIASIS; LUTZOMYIA LONGIPALPIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PSYCHODIDAE; SALIVA; STROMA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW CELLS; FEMALE; FIBROBLASTS; HEMATOPOIESIS; INSECT PROTEINS; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; NEUROPEPTIDES; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PSYCHODIDAE; RETICULOCYTES; SALIVARY PROTEINS; STROMAL CELLS; VASODILATOR AGENTS;

ANIMALIA; LEISHMANIA MAJOR; LUTZOMYIA LONGIPALPIS; PHLEBOTOMINAE; PROTOZOA; PSYCHODIDAE; VERTEBRATA;

EID: 0036428750     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.2002.00484.x     Document Type: Article

References (39)

1. Gillespie RD, Mbow ML, Titus RG. The immunomodulatory factors of bloodfeeding arthropod saliva. Parasite Immunol 2000; 22: 319-331.
2. Moro O, Lerner EA. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 1997; 272: 966-970.
3. Soares MBP, Titus RG, Shoemaker CB, David JR, Bozza M. The vasoactive peptide Maxadilan from sand fly saliva inhibits TNF-a and induces IL-6 by mouse macrophages through interaction with the PACAP receptor. J Immunol 1998; 160: 1811-1816.
4. Cai Y, Xin X, Shim G et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology 1997; 138: 2515-2520.
5. Chiu CP, Moulds C, Coffman RL, Rennick D, Lee F. Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci USA 1988; 85: 7099-7103.
6. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987; 84: 9035-9039.
7. Ulich TR, del Castillo J, Yin SM, Egrie JC. The erythropoietic effects of interleukin 6 and erythropoietin in vivo. Exp Hematol 1991; 19: 29-34.
8. Wong GG, Witek-Giannotti JS, Temple PA et al. Stimulation of murine hematopoietic colony formation by human IL-6. J Immunol 1988; 140: 3040-3044.
9. Sui X, Tsuji K, Tajima S et al. Erythropoietin-independent erythrocyte production: Signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells. J Exp Med 1996; 183: 837-845.
10. Mirkovich AM, Galelli AC, Modabber FZ. Increased myelopoiesis during Leishmania major infection in mice. Generation of 'safe targets', a possible way to evade the effector immune mechanism. Clin Exp Immunol 1986; 64: 1-7.
11. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sand fly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001; 167: 5226-5230.
12. Lanzaro GC, Lopes AHCS, Ribeiro JMC et al. Variation in the salivary peptide, maxadilan, from species in the Lutzomyia longipalpis complex. Insect Mol Biol 1999; 8: 267-275.
13. Coffman RL, Varkila K, Scott P, Chatelain R. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 1991; 123: 189-207.
14. DeKrey GK, Lima HC, Titus RG. Analysis of the immune responses of mice to infection with Leishmania braziliensis. Infect Immun 1998; 66: 827-829.
15. Titus RG, Kelso A, Louis JA. Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin Exp Immunol 1984; 55: 157-165.
16. Eaves CJ, Cashman JD, Eaves AC. Methodology of long-term culture of human hematopoietic cells. J Tissue Culture Meth 1991; 13: 55-62.
17. Chen Z, Van Bockstaele DR, Buyssens N et al. Stromal populations and fibrosis in human long-term bone marrow cultures. Leukemia 1991; 5: 772-781.
18. Chakkalath HR, Titus RG. Leishmania major-parasitized macrophages augment Th2-type T cell activation. J Immunol 1994; 153: 4378-4387.
19. Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002; 209: 1-7.
20. Titus RG, Ribeiro JMC. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-1308.
21. Stark R, Andre C, Thierry D, Cherel M, Galibert F, Gluckman E. The expression of cytokine and cytokine receptor genes in long-term bone marrow culture in congenital and acquired bone marrow hypoplasia. Br J Haematol 1993; 83: 560-566.
22. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haematopoietic stem cells in vitro. J Cell Physiol 1977; 91: 335-344.
23. Migliaccio AR, Migliaccio G. The making of an erythroid cell. Biotherapy 1998; 10: 251-268.
24. Michurina TV, Khrushchov NG. Experimental analysis of cell interactions during hematopoiesis. Int J Dev Biol 1997; 41: 817-833.
25. Mayani H, Guilbert MH, Janowska-Wieczorek A. Biology of the hematopoietic microenvironment. Eur J Haematol 1992; 49: 225-233.
26. Samardzic T, Jankovic V, Stosic-Grujicic S, Trajkovic V. STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts. Cytokine 2001; 13: 179-182.
27. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect 2000; 2: 1765-1773.
28. Theodos CM, Ribeiro JMC, Titus RG. Analysis of enhancing effect of sand fly saliva on Leishmania infection in mice. Infect Immun 1991; 59: 1592-1598.
29. Mbow ML, Bleyenberg JA, Hall LR, Titus RG. Phlebotomus papatasi sand fly salivary gland lysate downregulates a Th1, but upregulates a Th2, response in mice infected with Leishmania major. J Immunol 1998; 161: 5571-5577.
30. Belkaid Y, Kamhawi S, Modi G et al. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-1953.
31. Valenzuela JG, Belkaid Y, Garfield MK et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: Characterization of a protective salivary protein. J Exp Med 2001; 194: 331-342.
32. Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1994; 1: 725-731.
33. Martinez C, Delgado M, Pozo D et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: In vitro andin vivo studies. J Neuroimmunol 1998; 85: 155-167.
34. Delgado M, De la Fuente M, Martinez C, Gomariz RP. Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: Comparison with VIP and implication of cAMP. J Neuroimmunol 1995; 62: 137-146.
35. Delgado M, Garrido E, De la Fuente M, Gomariz RP. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. Peptides 1996; 17: 1097-1105.
36. Tornoe K, Hannibal J, Fahrenkrug J, Holst JJ. PACAP-(1-38) as neurotransmitter in pig pancreas: Receptor activation revealed by the antagonist PACAP-(6-38). Am J Physiol 1997; 273: G436-G446.
37. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994; 43: 111-123.
38. Sunderkotter C, Kunz M, Steinbrink K et al. Resistance of mice to experimental leishmaniasis is associated with more rapid appearance of mature macrophages in vitro andin vivo. J Immunol 1993; 151: 4891-4901.
39. Cotterell SE, Engwerda CR, Kaye PM. Leishmania donovani infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF-α. Blood 2000; 95: 1642-1651.